Impact Biomedical Inc. key statistics and ratios

In fiscal 2025, Impact Biomedical Inc. had return on equity of -56.5%, an operating margin of -13381.3%, debt equal to 0.0% of equity and a current ratio of 0.35. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Impact Biomedical Inc.: financial ratios, annual
Fiscal year	2022Dec 2022	2025Dec 2025	LTMJun 2026
Operating margin	<−999%	<−999%	<−999%
Net margin	<−999%	<−999%	>999%
Return on equity	−24.5%	−56.5%	6.8%
Return on assets	−15.6%	−37.1%	4.6%
Asset turnover	0.00	0.00	0.00
Current ratio	0.01	0.35	0.16
Debt to equity	33.8%	0.0%	0.0%
Interest cover (operating income ÷ interest)	n/m	n/m	—
R&D as % of revenue	>999%	>999%	811.4%
SG&A as % of revenue	650.0%	>999%	>999%

US$ thousands unless shown otherwise. Fiscal quarters.

Impact Biomedical Inc.: financial ratios, quarterly
Quarter	2022 Q2Jun 2022	2022 Q3Sept 2022	2022 Q4Dec 2022	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Gross margin	—	—	—	85.7%	94.4%	—	—	66.7%
Operating margin	<−999%	—	—	<−999%	<−999%	<−999%	<−999%	<−999%
Net margin	<−999%	—	—	<−999%	<−999%	>999%	<−999%	<−999%
Current ratio	—	—	0.01	0.06	0.04	0.35	0.22	0.16
R&D as % of revenue	412.0%	—	—	>999%	288.9%	>999%	657.1%	>999%
SG&A as % of revenue	116.0%	—	—	>999%	>999%	>999%	>999%	>999%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

0 of 3 checks passed · June 30, 2026

What it owns · $17m

Short-term assets $0mLonger-term assets $16m

What it owes, and who funded it · $13m

Short-term liabilities $2mLonger-term liabilities $1mShareholders' equity $11m

Short-term assets cover short-term liabilities $320,000 of assets due within a year against $2m of liabilities due within a year.
Short-term assets cover long-term liabilities $320,000 short-term assets against $688,000 of longer-dated liabilities.
More cash than debt Cash or debt not separately reported. Not assessable.
Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
Operating profit covers interest at least five times over Operating income of −$5m against $793,000 of interest.

From Impact Biomedical Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: IBO vs LYEL AIM vs IBO IBIO vs IBO

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Impact Biomedical Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Impact Biomedical Inc.